Rise and shine, everyone, another busy day is on the way. This will, in fact, prove to be an especially busy one for us, since we will be ensconced in a day-long industry gathering. So posting today may be a bit spotty. Of course, breaking away from the trusty laptop can be a good thing, now and then. And we will be all eyes and ears as we practice our hobnobbing. Meanwhile, here are a few items of interest to help you on your own journey. Hope your day is productive and we look forward to catching up….
Merck (MRK) raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling Keytruda cancer treatment, Reuters reports. The list price increases are the first that the company made since pledging in July that it would not raise the average net price of all of its medicines by more than the inflation rate. A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.
Since there is no transparency on “all [Merck] medicines.” how shall we rate the truth of this statement. “A Merck spokeswoman says the average net price, including rebates and discounts, fell 1.9 percent in the U.S. last year.”
For clarity it ranks with, “to the best of my recollection” – if below “I cannot recall, Senator.”
Comments are closed.